ProCE Banner Activity

CE

The Evolving Understanding of IgA Nephropathy: Implications of New Treatment for Managed Care Pharmacy Professionals

Video

In this on-demand webcast from a live symposium, expert faculty will discuss IgA nephropathy, pathophysiology, new and emerging therapies, and methods to address economic and disease burden in the managed care setting, from ProCE

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: November 02, 2023

Expiration: November 01, 2024

Share

Faculty

Michelle M. Richardson

Michelle M. Richardson, PharmD, BCPS

Special and Scientific Staff
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Silvia Titan

Silvia Titan, MD, PhD

Senior Associate Consultant
Nephrology Division, Mayo Clinic
Rochester, Minnesota

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Calliditas Therapeutics.

Calliditas Therapeutics

Target Audience

This program is intended for managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of pharmacist learners about new and emerging therapies for IgAN.

Learning Objectives

  • Describe the current understanding of the pathogenesis and pathophysiology of IgA nephropathy in alignment with available and potential treatment targets

  • Analyze the pharmacology and clinical outcomes data for recently FDA-approved and emerging therapies to facilitate optimal integration into treatment algorithms/clinical pathways

  • Examine the economic and clinical burden of IgA nephropathy and opportunities for managed care interventions to improve costs and patient outcomes

Disclosure

ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Michelle M. Richardson, PharmD, BCPS

Special and Scientific Staff
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Michelle M. Richardson, PharmD, BCPS, has no relevant financial relationships to disclose.

Silvia Titan, MD, PhD

Senior Associate Consultant
Nephrology Division, Mayo Clinic
Rochester, Minnesota

Silvia Titan, MD, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 02, 2023, through November 01, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-027-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.